Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review

MUCIN 1 in Prostate Cancer

Anil Kapoor  1   2   3 , Yan Gu  1   2   3 , Xiaozeng Lin  1   2   3 , Jingyi Peng  1   2   3 , Pierre Major  4 , Damu Tang  1   2   3
Simon RJ Bott  1 , Keng Lim Ng  1
, editors.
In: Prostate Cancer [Internet]. Brisbane (AU): Exon Publications; 2021 May 27. Chapter 9.
Affiliations
Free Books & Documents
Review

MUCIN 1 in Prostate Cancer

Anil Kapoor et al.
Free Books & Documents

Excerpt

Despite extensive research efforts in prostate cancer for the last several decades, the disease remains a leading cause of cancer death in men in the developed world. A typical feature of prostate cancer initiation and progression is the landscape of genetic alterations, which changes the expression patterns of numerous molecules in prostate epithelial cells, where the disease originates. These aberrantly expressed proteins are tumor-associated antigens. Their uniqueness in tumors offers an avenue not only in advancing our understanding of prostate cancer but also in the search for better diagnostic and therapeutic tools. Mucin 1 is one of the most well-characterized tumor-associated antigens. The protein is overexpressed and aberrantly glycosylated following prostate cancer development, and influences certain disease factors including disease initiation, metastasis, and resistance to therapy. Mucin 1 possesses value as a biomarker in predicting prostate cancer prognosis and has been studied as a therapeutic target. This chapter provides an overview of the impact of Mucin 1 on prostate cancer and its clinical values.

PubMed Disclaimer

References

    1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA: a cancer journal for clinicians. 2011;61(4):212–36. https://doi.org/10.3322/caac.20121. - DOI - PubMed
    1. Ross JS. The androgen receptor in prostate cancer: therapy target in search of an integrated diagnostic test. Adv Anat Pathol. 2007;14(5):353–7. https://doi.org/10.1097/PAP.0b013e31814a52c4. - DOI - PubMed
    1. Moon C, Park JC, Chae YK, Yun JH, Kim S. Current status of experimental therapeutics for prostate cancer. Cancer Lett. 2008;266(2):116–34. https://doi.org/10.1016/j.canlet.2008.02.065. - DOI - PubMed
    1. Bagnall P. Diagnosis and treatment of prostate cancer. Nurs Times. 2014;110(9):12–5. - PubMed
    1. Zaorsky NG, Raj GV, Trabulsi EJ, Lin J, Den RB. The dilemma of a rising prostate-specific antigen level after local therapy: what are our options? Semin Oncol. 2013;40(3):322–36. https://doi.org/10.1053/j.seminoncol.2013.04.011. - DOI - PubMed

LinkOut - more resources